ResMed Deferred Long Term Liab vs Total Liab Analysis

RMD Stock

USD 243.78 0.18 0.07%

ResMed financial indicator trend analysis is much more than just breaking down ResMed Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ResMed Inc is a good investment. Please check the relationship between ResMed Deferred Long Term Liab and its Total Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Deferred Long Term Liab vs Total Liab

Deferred Long Term Liab vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ResMed Inc Deferred Long Term Liab account and Total Liab. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between ResMed's Deferred Long Term Liab and Total Liab is -0.12. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Total Liab in the same time period over historical financial statements of ResMed Inc, assuming nothing else is changed. The correlation between historical values of ResMed's Deferred Long Term Liab and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of ResMed Inc are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Deferred Long Term Liab i.e., ResMed's Deferred Long Term Liab and Total Liab go up and down completely randomly.

Correlation Coefficient

-0.12

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from ResMed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ResMed Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At present, ResMed's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 451 M, whereas Issuance Of Capital Stock is forecasted to decline to about 49.9 M.

	2021	2022	2023	2024 (projected)
Gross Profit	2.0B	2.4B	2.6B	2.7B
Total Revenue	3.6B	4.2B	4.7B	4.9B

Gross Profit Total Revenue

ResMed fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant And Equipment Gross	Common Stock Total Equity	Short Term Investments
Total Assets		0.58	0.63	0.89	0.97	0.92	0.74	0.98	0.95	-0.33	0.98	0.54	-0.33	0.97	0.56	0.8	0.95	0.93	0.62	0.91	0.88	-0.11	0.9	0.85	0.46	0.71
Short Long Term Debt Total	0.58		0.28	0.46	0.39	0.43	0.79	0.46	0.39	-0.11	0.59	0.57	-0.11	0.46	0.4	0.9	0.5	0.33	0.07	0.83	0.45	0.18	0.75	0.15	0.48	0.5
Other Current Liab	0.63	0.28		0.8	0.57	0.62	0.53	0.58	0.58	-0.45	0.68	0.61	-0.45	0.64	0.39	0.47	0.53	0.49	0.44	0.63	0.39	-0.32	0.66	0.44	0.35	0.61
Total Current Liabilities	0.89	0.46	0.8		0.87	0.86	0.63	0.88	0.87	-0.28	0.89	0.49	-0.28	0.9	0.57	0.63	0.79	0.79	0.51	0.82	0.76	0.08	0.81	0.77	0.48	0.61
Total Stockholder Equity	0.97	0.39	0.57	0.87		0.93	0.59	0.99	0.97	-0.29	0.93	0.42	-0.29	0.97	0.54	0.65	0.95	0.97	0.68	0.79	0.91	-0.14	0.78	0.93	0.42	0.65
Property Plant And Equipment Net	0.92	0.43	0.62	0.86	0.93		0.47	0.92	0.89	-0.05	0.84	0.44	-0.05	0.92	0.75	0.62	0.86	0.87	0.55	0.76	0.95	-0.07	0.7	0.83	0.64	0.53
Net Debt	0.74	0.79	0.53	0.63	0.59	0.47		0.64	0.6	-0.65	0.83	0.69	-0.65	0.63	0.14	0.92	0.72	0.58	0.45	0.9	0.4	-0.19	0.94	0.37	0.14	0.82
Retained Earnings	0.98	0.46	0.58	0.88	0.99	0.92	0.64		0.98	-0.31	0.95	0.47	-0.3	0.98	0.56	0.7	0.94	0.95	0.6	0.83	0.9	-0.09	0.82	0.9	0.45	0.64
Accounts Payable	0.95	0.39	0.58	0.87	0.97	0.89	0.6	0.98		-0.3	0.93	0.34	-0.3	0.96	0.52	0.65	0.88	0.92	0.58	0.79	0.85	-0.13	0.8	0.94	0.4	0.64
Cash	-0.33	-0.11	-0.45	-0.28	-0.29	-0.05	-0.65	-0.31	-0.3		-0.48	-0.52	1.0	-0.29	0.39	-0.35	-0.42	-0.36	-0.53	-0.36	0.1	0.56	-0.5	-0.18	0.35	-0.73
Non Current Assets Total	0.98	0.59	0.68	0.89	0.93	0.84	0.83	0.95	0.93	-0.48		0.59	-0.48	0.94	0.45	0.83	0.93	0.89	0.64	0.93	0.78	-0.19	0.95	0.8	0.37	0.79
Non Currrent Assets Other	0.54	0.57	0.61	0.49	0.42	0.44	0.69	0.47	0.34	-0.52	0.59		-0.52	0.49	0.33	0.66	0.57	0.41	0.27	0.66	0.31	-0.29	0.63	0.09	0.38	0.52
Cash And Short Term Investments	-0.33	-0.11	-0.45	-0.28	-0.29	-0.05	-0.65	-0.3	-0.3	1.0	-0.48	-0.52		-0.28	0.4	-0.35	-0.42	-0.36	-0.53	-0.36	0.1	0.56	-0.5	-0.18	0.35	-0.73
Net Receivables	0.97	0.46	0.64	0.9	0.97	0.92	0.63	0.98	0.96	-0.29	0.94	0.49	-0.28		0.62	0.7	0.9	0.9	0.54	0.84	0.88	-0.11	0.84	0.88	0.52	0.61
Common Stock Shares Outstanding	0.56	0.4	0.39	0.57	0.54	0.75	0.14	0.56	0.52	0.39	0.45	0.33	0.4	0.62		0.41	0.41	0.4	-0.03	0.51	0.73	0.19	0.4	0.44	0.92	0.01
Non Current Liabilities Total	0.8	0.9	0.47	0.63	0.65	0.62	0.92	0.7	0.65	-0.35	0.83	0.66	-0.35	0.7	0.41		0.74	0.6	0.35	0.96	0.59	-0.11	0.93	0.42	0.39	0.7
Inventory	0.95	0.5	0.53	0.79	0.95	0.86	0.72	0.94	0.88	-0.42	0.93	0.57	-0.42	0.9	0.41	0.74		0.97	0.74	0.82	0.84	-0.19	0.81	0.79	0.33	0.76
Other Current Assets	0.93	0.33	0.49	0.79	0.97	0.87	0.58	0.95	0.92	-0.36	0.89	0.41	-0.36	0.9	0.4	0.6	0.97		0.76	0.72	0.87	-0.17	0.72	0.89	0.29	0.7
Other Stockholder Equity	0.62	0.07	0.44	0.51	0.68	0.55	0.45	0.6	0.58	-0.53	0.64	0.27	-0.53	0.54	-0.03	0.35	0.74	0.76		0.44	0.48	-0.4	0.49	0.62	-0.11	0.75
Total Liab	0.91	0.83	0.63	0.82	0.79	0.76	0.9	0.83	0.79	-0.36	0.93	0.66	-0.36	0.84	0.51	0.96	0.82	0.72	0.44		0.71	-0.06	0.98	0.59	0.46	0.73
Total Current Assets	0.88	0.45	0.39	0.76	0.91	0.95	0.4	0.9	0.85	0.1	0.78	0.31	0.1	0.88	0.73	0.59	0.84	0.87	0.48	0.71		0.11	0.63	0.82	0.61	0.41
Short Term Debt	-0.11	0.18	-0.32	0.08	-0.14	-0.07	-0.19	-0.09	-0.13	0.56	-0.19	-0.29	0.56	-0.11	0.19	-0.11	-0.19	-0.17	-0.4	-0.06	0.11		-0.16	-0.09	0.19	-0.44
Intangible Assets	0.9	0.75	0.66	0.81	0.78	0.7	0.94	0.82	0.8	-0.5	0.95	0.63	-0.5	0.84	0.4	0.93	0.81	0.72	0.49	0.98	0.63	-0.16		0.62	0.36	0.79
Property Plant And Equipment Gross	0.85	0.15	0.44	0.77	0.93	0.83	0.37	0.9	0.94	-0.18	0.8	0.09	-0.18	0.88	0.44	0.42	0.79	0.89	0.62	0.59	0.82	-0.09	0.62		0.3	0.5
Common Stock Total Equity	0.46	0.48	0.35	0.48	0.42	0.64	0.14	0.45	0.4	0.35	0.37	0.38	0.35	0.52	0.92	0.39	0.33	0.29	-0.11	0.46	0.61	0.19	0.36	0.3		0.05
Short Term Investments	0.71	0.5	0.61	0.61	0.65	0.53	0.82	0.64	0.64	-0.73	0.79	0.52	-0.73	0.61	0.01	0.7	0.76	0.7	0.75	0.73	0.41	-0.44	0.79	0.5	0.05

Click cells to compare fundamentals

ResMed Account Relationship Matchups

ResMed fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.6B	4.7B	5.1B	6.8B	6.9B	7.2B
Short Long Term Debt Total	1.3B	793.7M	917.6M	1.6B	873.9M	448.1M
Other Current Liab	335.1M	749.2M	322.9M	343.7M	352.4M	370.0M
Total Current Liabilities	602.8M	911.8M	689.3M	758.5M	910.7M	956.2M
Total Stockholder Equity	2.5B	2.9B	3.4B	4.1B	4.9B	5.1B
Property Plant And Equipment Net	535.7M	592.1M	630.5M	665.8M	699.1M	734.1M
Net Debt	836.1M	498.4M	643.8M	1.4B	635.6M	667.4M
Retained Earnings	2.8B	3.1B	3.6B	4.3B	5.0B	5.2B
Accounts Payable	135.8M	138.0M	159.2M	150.8M	237.7M	249.6M
Cash	463.2M	295.3M	273.7M	227.9M	238.4M	333.5M
Non Current Assets Total	3.1B	3.2B	3.2B	4.4B	4.5B	4.7B
Non Currrent Assets Other	189.7M	240.8M	251.5M	395.4M	114.2M	73.7M
Cash And Short Term Investments	463.2M	295.3M	273.7M	227.9M	238.4M	338.0M
Net Receivables	474.6M	614.3M	576.0M	704.9M	837.3M	879.1M
Common Stock Shares Outstanding	145.7M	146.5M	147.0M	147.5M	147.6M	147.7M
Liabilities And Stockholders Equity	4.6B	4.7B	5.1B	6.8B	6.9B	7.2B
Non Current Liabilities Total	1.5B	930.7M	1.0B	1.9B	1.1B	1.2B
Inventory	416.9M	457.0M	743.9M	998.0M	822.3M	863.4M
Other Current Assets	168.7M	208.2M	337.9M	437.0M	459.8M	482.8M
Other Stockholder Equity	(52.6M)	(1.1M)	59.2M	148.8M	123.3M	129.5M
Total Liab	2.1B	1.8B	1.7B	2.6B	2.0B	2.1B
Total Current Assets	1.5B	1.6B	1.9B	2.4B	2.4B	2.5B
Short Term Debt	33.3M	35.6M	53.6M	53.7M	60.5M	68.6M
Intangible Assets	448.2M	392.6M	345.9M	552.3M	485.9M	510.2M
Property Plant And Equipment Gross	535.7M	592.1M	630.5M	665.8M	1.4B	1.5B
Accumulated Other Comprehensive Income	(284.0M)	(193.5M)	(312.7M)	(272.5M)	(251.5M)	(239.0M)
Common Stock Total Equity	571K	575K	580K	583K	670.5K	417.0K
Common Stock	580K	583K	586K	588K	676.2K	443.7K
Other Assets	145.6M	240.8M	202.3M	261.3M	300.5M	315.5M
Good Will	1.9B	1.9B	1.9B	2.8B	2.8B	3.0B
Property Plant Equipment	535.7M	592.1M	630.5M	665.8M	765.7M	384.1M
Other Liab	221.6M	172.6M	160.0M	315.2M	362.5M	380.6M
Long Term Debt	1.2B	643.4M	765.3M	1.4B	697.3M	482.4M
Current Deferred Revenue	98.6M	109.6M	108.7M	138.1M	152.6M	160.2M
Net Tangible Assets	158.5M	565.2M	1.1B	807.3M	726.5M	632.7M
Long Term Debt Total	1.3B	1.2B	643.4M	765.3M	880.1M	737.7M
Capital Surpluse	1.5B	1.6B	1.6B	1.7B	1.9B	1.5B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:

How To Invest In ResMed

Details

Is ResMed Stock a good investment?

Details

What is ResMed's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.416

Dividend Share

1.97

Earnings Share

7.55

Revenue Per Share

32.711

Quarterly Revenue Growth

0.111

The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ResMed Deferred Long Term Liab vs Total Liab Analysis

Deferred Long Term Liab vs Total Liab

Deferred Long Term Liab vs Total Liab Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Total Liab

ResMed fundamental ratios Correlations

ResMed Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ResMed fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Retained Earnings	+ 0.99	Total Stockholder Equity
Retained Earnings	+ 0.98	Total Assets
Non Current Assets Total	+ 0.98	Total Assets
Accounts Payable	+ 0.98	Retained Earnings
Net Receivables	+ 0.98	Retained Earnings

Short Term Investments	- 0.73	Cash And Short Term Investments
Short Term Investments	- 0.73	Cash
Cash And Short Term Investments	- 0.65	Net Debt
Cash	- 0.65	Net Debt
Other Stockholder Equity	- 0.53	Cash And Short Term Investments
Other Stockholder Equity	- 0.53	Cash